在二甲双胍二联治疗中,吡格列酮相比其他二线治疗降低痴呆风险:一项基于人群的纵向研究
在台湾2000—2011年204,323例稳定使用二甲双胍的2型糖尿病患者中,比较不同二线降糖药与痴呆风险的关系,随访至2013年底。主要分析纳入51,415例年龄≥65岁且二线治疗第一年无痴呆事件者。结果显示二甲双胍+吡格列酮组痴呆风险显著低于二甲双胍+磺脲类组(HR 0.56;95% CI 0.34, 0.93),与其他二甲双胍二联方案相比风险较低但未达显著。
要点
- ≥65岁患者中,二甲双胍+吡格列酮较二甲双胍+磺脲类显著降低痴呆风险(HR 0.56;95% CI 0.34, 0.93)。
- 与其他二甲双胍二联方案相比,吡格列酮组痴呆风险较低但未达统计学显著。
- ≥18岁人群中,吡格列酮较其他二线降糖药痴呆风险降低;二甲双胍+吡格列酮较二甲双胍+罗格列酮痴呆发生率更低。
核心结论
- 在二甲双胍之后作为二线治疗的吡格列酮可能对2型糖尿病患者的痴呆风险提供保护作用。
研究设计与样本
- 基于台湾全民健康保险研究数据库2000—2011年数据、随访至2013年底的基于人群的纵向研究。
- 共纳入204,323例年龄≥18岁、稳定使用二甲双胍且启用二线降糖药前无痴呆的2型糖尿病患者。
- 主要分析纳入51,415例年龄≥65岁且二线降糖治疗第一年无痴呆事件者。
- 研究对象按与二甲双胍联用的不同二线降糖药分为互斥组,采用Cox比例风险模型在倾向评分匹配的治疗组间评估事件发生时间。
主要发现
- 年龄≥65岁者中,二甲双胍+吡格列酮组较二甲双胍+磺脲类组痴呆风险显著降低(HR 0.56;95% CI 0.34, 0.93)。
- 年龄≥65岁者中,二甲双胍+吡格列酮组较其他二甲双胍二联方案(二甲双胍+阿卡波糖、二甲双胍+瑞格列奈、二甲双胍+胰岛素或二甲双胍+二肽基肽酶4抑制剂)痴呆风险较低但未达统计学显著。
- 年龄≥18岁人群中,使用吡格列酮者较使用其他二线降糖药者痴呆风险亦降低。
- 二甲双胍+吡格列酮使用者较二甲双胍+罗格列酮使用者痴呆发生率更低。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: The effect of pioglitazone was compared with that of other second-line glucose-lowering drugs on the risk of dementia among individuals with type 2 diabetes receiving metformin-based dual therapy. METHODS: A total of 204,323 individuals with type 2 diabetes aged ≥18 years who were stable metformin users and dementia-free before the initiation of second-line glucose-lowering medication were identified in the period 2000-2011 from Taiwan's National Health Insurance Research Database and followed to the end of 2013. Primary analyses included 51,415 individuals aged ≥65 years without dementia events in the first year of second-line glucose-lowering treatment. Study subjects were classified into mutually exclusive groups according to various second-line glucose-lowering drugs to metformin. Cox proportional hazards models were applied to assess the time-to-event between propensity score-matched glucose-lowering treatment groups. RESULTS: Individuals aged ≥65 years on metformin + pioglitazone had a significantly lower risk of dementia compared with those on metformin + sulfonylurea (HR 0.56; 95% CI 0.34, 0.93), and a lower, but insignificant, risk of dementia compared with those on other metformin-based dual regimens (i.e. metformin + acarbose, metformin + meglitinide, metformin + insulin or metformin + dipeptidyl peptidase 4 inhibitors). Among individuals aged ≥18 years, there was also a decreased risk of dementia in those taking pioglitazone compared with those taking other second-line glucose-lowering drugs. A lower incidence of dementia was found in users of metformin + pioglitazone compared with users of metformin + rosiglitazone. CONCLUSIONS/INTERPRETATION: Pioglitazone as a second-line treatment after metformin might provide a protective effect on dementia risk among individuals with type 2 diabetes.
引用
- Lu CH, Yang CY, Li CY, et al. Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy: a population-based longitudinal study. Diabetologia. 2017. PMID: 29138876. doi:10.1007/s00125-017-4499-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。